Mahoney F. Michael's Insider Trades & SAST Disclosures
Mahoney F. Michael's most recent trade in CVS Health Corp was a trade of 30,000 Common Stock (By Trust) done at an average price of $66.7 . Disclosure was reported to the exchange on Feb. 18, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Mahoney F. Michael.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
CVS Health Corp
|
Michael F. Mahoney | Director | Purchase of securities on an exchange or from another person at price $ 66.70 per share. | 18 Feb 2025 | 30,000 | 39,356 (0%) | 0% | 66.7 | 2,001,000 | Common Stock (By Trust) |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 90,915 | 90,915 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 35,330 | 35,330 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 18,334 | 0 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 18,334 | 1,662,219 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,524 | 1,643,475 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,524 | 33,048 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,265 | 16,265 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,265 | 1,651,750 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 8,865 | 1,653,354 (0%) | 0% | 106.1 | 940,665 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 7,990 | 1,635,485 (0%) | 0% | 106.1 | 847,819 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 106.11 per share. | 13 Feb 2025 | 7,865 | 1,643,885 (0%) | 0% | 106.1 | 834,555 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 13,704 | 41,112 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 13,704 | 1,633,577 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.77 per share. | 12 Feb 2025 | 6,626 | 1,626,951 (0%) | 0% | 105.8 | 700,832 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 130,118 | 1,682,788 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 105.98 per share. | 11 Feb 2025 | 62,915 | 1,619,873 (0%) | 0% | 106.0 | 6,667,732 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 57,121 | 0 | - | - | Performance Share Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2025 | 57,121 | 1,578,326 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 89.32 per share. | 01 Jan 2025 | 25,656 | 1,552,670 (0%) | 0% | 89.3 | 2,291,594 | Common Stock |
|
Boston Scientific Corp.
|
F. Michael Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Nov 2024 | 7,800 | 201,478 (0%) | 0% | 0 | Common Stock | |
|
CVS Health Corp
|
Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 57.10 per share. | 21 Nov 2024 | 2,200 | 6,201 (0%) | 0% | 57.1 | 125,620 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.74 per share. | 05 Nov 2024 | 160,182 | 1,521,205 (0%) | 0% | 84.7 | 13,573,743 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2024 | 56,211 | 168,635 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 05 Nov 2024 | 56,211 | 1,628,307 (0%) | 0% | 17.3 | 970,202 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2024 | 55,676 | 0 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 05 Nov 2024 | 55,676 | 1,683,983 (0%) | 0% | 16.3 | 908,076 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 85.17 per share. | 05 Nov 2024 | 2,596 | 1,681,387 (0%) | 0% | 85.2 | 221,108 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.94 per share. | 07 Oct 2024 | 82,085 | 1,572,096 (0%) | 0% | 84.9 | 6,972,431 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 84.31 per share. | 07 Oct 2024 | 80,692 | 1,654,181 (0%) | 0% | 84.3 | 6,803,360 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 56,211 | 224,846 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 07 Oct 2024 | 56,211 | 1,679,198 (0%) | 0% | 17.3 | 970,202 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Oct 2024 | 55,675 | 55,676 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 07 Oct 2024 | 55,675 | 1,734,873 (0%) | 0% | 16.3 | 908,059 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 81.17 per share. | 05 Sep 2024 | 162,777 | 1,622,987 (0%) | 0% | 81.2 | 13,212,544 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.26 per share. | 05 Sep 2024 | 56,211 | 1,730,089 (0%) | 0% | 17.3 | 970,202 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2024 | 56,211 | 281,057 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 05 Sep 2024 | 55,675 | 1,785,764 (0%) | 0% | 16.3 | 908,059 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Sep 2024 | 55,675 | 111,351 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2024 | 176,245 | 209,278 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2024 | 114,237 | 290,482 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2024 | 95,041 | 385,523 (0%) | 0% | 0 | Common Stock | |
|
CVS Health Corp
|
Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 57.52 per share. | 16 May 2024 | 2,184 | 4,001 (0%) | 0% | 57.5 | 125,624 | Common Stock |
|
CVS Health Corp
|
Michael F. Mahoney | Director | Purchase of securities on an exchange or from another person at price $ 54.49 per share. | 02 May 2024 | 9,181 | 9,356 (0%) | 0% | 54.5 | 500,294 | Common Stock (By Trust) |
|
Boston Scientific Corp.
|
F. Mahoney Michael | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 18,333 | 18,334 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Mahoney Michael F. | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 18,333 | 1,672,935 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Mahoney Michael F. | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,307 | 1,681,111 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Mahoney F. Michael | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,307 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,265 | 32,530 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
F. Mahoney Michael | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 16,265 | 1,661,816 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael Mahoney F. | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 8,131 | 1,664,804 (0%) | 0% | 65.8 | 535,182 | Common Stock |
|
Boston Scientific Corp.
|
Mahoney Michael F. | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 7,233 | 1,673,878 (0%) | 0% | 65.8 | 476,076 | Common Stock |
|
Boston Scientific Corp.
|
Mahoney F. Michael | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.82 per share. | 16 Feb 2024 | 7,214 | 1,654,602 (0%) | 0% | 65.8 | 474,825 | Common Stock |
|
Boston Scientific Corp.
|
Mahoney Michael F. | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 16,523 | 1,652,879 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
F. Mahoney Michael | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Feb 2024 | 16,523 | 49,572 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
F. Mahoney Michael | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 65.95 per share. | 14 Feb 2024 | 7,328 | 1,645,551 (0%) | 0% | 66.0 | 483,282 | Common Stock |
|
Boston Scientific Corp.
|
Michael Mahoney F. | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 144,516 | 144,516 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 54,816 | 54,816 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 146,666 | 1,701,403 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
F. Michael Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 06 Feb 2024 | 65,047 | 1,636,356 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
F. Mahoney Michael | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 95,919 | 0 | - | - | Performance Share Units | |
|
Boston Scientific Corp.
|
Michael Mahoney F. | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jan 2024 | 95,919 | 1,594,841 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Mahoney Michael F. | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.81 per share. | 01 Jan 2024 | 40,104 | 1,554,737 (0%) | 0% | 57.8 | 2,318,412 | Common Stock |
|
CVS Health Corp
|
Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 69.13 per share. | 15 Nov 2023 | 1,817 | 1,817 (0%) | 0% | 69.1 | 125,609 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 52.51 per share. | 06 Nov 2023 | 113,356 | 1,498,922 (0%) | 0% | 52.5 | 5,951,983 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2023 | 57,681 | 0 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.08 per share. | 06 Nov 2023 | 57,681 | 1,556,603 (0%) | 0% | 13.1 | 754,467 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 06 Nov 2023 | 55,675 | 1,612,278 (0%) | 0% | 16.3 | 908,059 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2023 | 55,675 | 167,026 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 52.09 per share. | 09 Oct 2023 | 113,355 | 1,498,922 (0%) | 0% | 52.1 | 5,904,481 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2023 | 57,680 | 57,681 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.08 per share. | 09 Oct 2023 | 57,680 | 1,556,602 (0%) | 0% | 13.1 | 754,454 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 09 Oct 2023 | 55,675 | 1,612,277 (0%) | 0% | 16.3 | 908,059 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2023 | 55,675 | 222,701 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Sale of securities on an exchange or to another person at price $ 53.91 per share. | 12 Sep 2023 | 113,355 | 1,498,922 (0%) | 0% | 53.9 | 6,110,447 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2023 | 57,680 | 115,361 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.08 per share. | 12 Sep 2023 | 57,680 | 1,556,602 (0%) | 0% | 13.1 | 754,454 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.31 per share. | 12 Sep 2023 | 55,675 | 1,612,277 (0%) | 0% | 16.3 | 908,059 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2023 | 55,675 | 278,376 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2023 | 318,218 | 1,498,922 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2023 | 141,450 | 175,150 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 30 Aug 2023 | 1,095 | 176,245 (0%) | 0% | 0 | Common Stock | |
|
Baxter International Inc.
|
Michael F. Mahoney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 4,573 | 9,692 (0%) | 0% | 0 | Common Stock, $1 par value | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 16,825 | 1,858,302 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2023 | 16,825 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.23 per share. | 21 Feb 2023 | 7,462 | 1,850,840 (0%) | 0% | 46.2 | 344,968 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 18,333 | 36,667 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 18,333 | 1,840,534 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 16,307 | 16,307 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 16,307 | 1,848,710 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 16,264 | 1,829,415 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 16,264 | 48,795 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.54 per share. | 16 Feb 2023 | 8,131 | 1,832,403 (0%) | 0% | 46.5 | 378,417 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.54 per share. | 16 Feb 2023 | 7,233 | 1,841,477 (0%) | 0% | 46.5 | 336,624 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 46.48 per share. | 16 Feb 2023 | 7,214 | 1,822,201 (0%) | 0% | 46.5 | 335,307 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 18,457 | 1,821,337 (0%) | 0% | 0 | Common Stock | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 18,457 | 0 | - | - | Deferred Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 47.29 per share. | 15 Feb 2023 | 8,186 | 1,813,151 (0%) | 0% | 47.3 | 387,116 | Common Stock |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 171,984 | 171,984 | - | - | Stock Option (Right to Buy) | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 66,095 | 66,095 | - | - | Restricted Stock Units | |
|
Boston Scientific Corp.
|
Michael F. Mahoney | Director, Chairman, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 57,121 | 57,121 | - | - | Performance Share Units |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges